Advisory Board on Radiation and Worker Health, 26474-26475 [2020-09400]
Download as PDF
<![CDATA[
26474
Federal Register / Vol. 85, No. 86 / Monday, May 4, 2020 / Notices
A recommendation vote is scheduled for
influenza vaccines and a VFC vote is
schedule for meningococcal vaccines.
Agenda items are subject to change as
priorities dictate. For more information
on the meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: April 28, 2020.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09403 Filed 5–1–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0050]
Advisory Board on Radiation and
Worker Health
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
of the Advisory Board on Radiation and
Worker Health (ABRWH). This meeting
is open to the public, but without an
oral public comment period. The public
is welcome to listen to the meeting by
joining the audio conference
(information below). The audio
conference line has 150 ports for callers.
DATES: The meeting will be held on June
24, 2020, 11 a.m. to 1 p.m., EDT.
Written comments must be received
on or before June 18, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0050 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Rashaun Roberts, Ph.D.,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:03 May 01, 2020
Jkt 250001
C–24, Atlanta, GA 30329–4027, Attn:
ABRWH Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Meeting information: The USA tollfree dial-in number is 1–866–659–0537;
the pass code is 9933701.
FOR FURTHER INFORMATION CONTACT:
Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090
Tusculum Avenue, Mailstop C–24,
Cincinnati, Ohio 45226, Telephone
(513) 533–6800, Toll Free 1(800)CDC–
INFO, Email ocas@cdc.gov.
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule, advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule, advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program, and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC). In
December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS,
which subsequently delegated this
authority to the CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
and rechartered under Executive Order
13889 on March 22, 2020, and will
terminate on March 22, 2022.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Public Participation
Written Public Comment: The public
is welcome to submit written comments
in advance of the meeting. Comments
should be submitted on or before June
18, 2020. All requests must contain the
name, address, and organizational
affiliation of the individual, as well as
the topic being addressed. Written
comments should not exceed one singlespaced typed page in length. Written
comments received in advance of the
meeting will be included in the official
record of the meeting.
Comments received, including
attachments and other supporting
materials, are part of the public record
and are subject to public disclosure.
Comments will be posted on https://
www.regulations.gov. Therefore, do not
include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. CDC will carefully
consider all comments submitted to the
docket.
Matters to be Considered: The agenda
will include discussions on: Work
Group and Subcommittee Reports;
Update on the Status of SEC Petitions;
Plans for the August 2020 Advisory
Board Meeting; and Advisory Board
Correspondence. Agenda items are
subject to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
E:\FR\FM\04MYN1.SGM
04MYN1
Federal Register / Vol. 85, No. 86 / Monday, May 4, 2020 / Notices
Dated: April 28, 2020.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09400 Filed 5–1–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1724–N]
Medicare Program; Public Meeting on
June 22, 2020 Regarding New and
Reconsidered Clinical Diagnostic
Laboratory Test Codes for the Clinical
Laboratory Fee Schedule for Calendar
Year 2021
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice of meeting.
AGENCY:
This notice announces a
virtual public meeting to receive
comments and recommendations
(including data on which
recommendations are based) on the
appropriate basis for establishing
payment amounts for new or
substantially revised Healthcare
Common Procedure Coding System
codes being considered for Medicare
payment under the Clinical Laboratory
Fee Schedule (CLFS) for calendar year
(CY) 2021. This meeting also provides a
forum for those who submitted certain
reconsideration requests regarding final
determinations made last year on new
test codes and for the public to provide
comment on the requests.
DATES:
CLFS Annual Public Meeting Date:
The virtual meeting is scheduled for
Monday, June 22, 2020 from 8:30 a.m.
to 5:00 p.m., Eastern Daylight Time
(E.D.T.)
Deadline for Submission of
Presentations and Written Comments:
All presenters for the CLFS Annual
Public Meeting must register and submit
their presentations electronically to our
CLFS dedicated email box, CLFS_
Annual_Public_Meeting@cms.hhs.gov,
by June 4, 2020 at 5:00 p.m., E.D.T. All
written comments (non-presenter
comments) must also be submitted
electronically to our CLFS dedicated
email box, CLFS_Annual_Public_
Meeting@cms.hhs.gov, by June 4, 2020,
5:00 p.m., E.D.T. Any presentations or
written comments received after that
date and time will not be included in
the meeting and will not be reviewed.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:03 May 01, 2020
Jkt 250001
Deadline for Submitting Requests for
Special Accommodations: Requests for
special accommodations must be
received no later than June 4, 2020 at
5:00 p.m. E.D.T.
Publication of Proposed
Determinations: We intend to publish
our proposed determinations for new
test codes and our preliminary
determinations for reconsidered codes
(as described later in section II
‘‘Format’’ of this notice) for CY 2021 by
early September 2020.
Deadline for Submission of Written
Comments Related to Proposed
Determinations: Comments in response
to the preliminary determinations will
be due by early October 2020.
ADDRESSES: Due to the current COVID–
19 public health emergency, the CLFS
Annual Public Meeting will be held
virtually and will not occur at the
campus of the Centers for Medicare &
Medicaid Services (CMS), Central
Building, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
Where to Submit Written Comments:
Interested parties should submit all
written comments on presentations and
preliminary determinations to the
address specified in this section of this
notice or electronically to our CLFS
dedicated email box, CLFS_Annual_
Public_Meeting@cms.hhs.gov (the
specific date for the publication of these
determinations and the deadline for
submitting comments regarding these
determinations will be published on the
CMS website).
FOR FURTHER INFORMATION CONTACT:
Rasheeda Arthur, Ph.D., (410) 786–3434.
Submit all inquiries to the CLFS
dedicated email box, CLFS_Annual_
Public_Meeting@cms.hhs.gov with the
subject entitled ‘‘CLFS Annual Public
Meeting Inquiry.’’
SUPPLEMENTARY INFORMATION:
I. Background
Section 531(b) of the Medicare,
Medicaid, and SCHIP Benefits
Improvement and Protection Act of
2000 (BIPA) (Pub. L. 106–554) required
the Secretary of the Department of
Health and Human Services (the
Secretary) to establish procedures for
coding and payment determinations for
new clinical diagnostic laboratory tests
under Part B of title XVIII of the Social
Security Act (the Act) that permit public
consultation in a manner consistent
with the procedures established for
implementing coding modifications for
International Classification of Diseases
Tenth Revision, Clinical Modification
(ICD–10–CM). The procedures and
Clinical Laboratory Fee Schedule
(CLFS) public meeting announced in
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
26475
this notice for new tests are in
accordance with the procedures
published on November 23, 2001 in the
Federal Register (66 FR 58743) to
implement section 531(b) of BIPA.
Section 942(b) of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) (Pub.
L. 108–173) added section 1833(h)(8) of
the Act. Section 1833(h)(8)(A) of the Act
requires the Secretary to establish by
regulation procedures for determining
the basis for, and amount of, payment
for any clinical diagnostic laboratory
test (CDLT) for which a new or
substantially revised Healthcare
Common Procedure Coding System
code is assigned on or after January 1,
2005. A code is considered to be
substantially revised if there is a
substantive change to the definition of
the test or procedure to which the code
applies (for example, a new analyte or
a new methodology for measuring an
existing analyte-specific test). (See
section 1833(h)(8)(E)(ii) of the Act and
42 CFR 414.502).
Section 1833(h)(8)(B) of the Act sets
forth the process for determining the
basis for, and the amount of, payment
for new tests. Pertinent to this notice,
sections 1833(h)(8)(B)(i) and (ii) of the
Act require the Secretary to make
available to the public a list that
includes any such test for which
establishment of a payment amount is
being considered for a year and, on the
same day that the list is made available,
cause to have published in the Federal
Register notice of a meeting to receive
comments and recommendations
(including data on which
recommendations are based) from the
public on the appropriate basis for
establishing payment amounts for the
tests on such list. This list of codes for
which the establishment of a payment
amount under the CLFS is being
considered for Calendar Year (CY) 2021
will be posted on the Centers for
Medicare & Medicaid Services (CMS)
website concurrent with the publication
of this notice and may be updated prior
to the CLFS Annual Public Meeting. The
CLFS Annual Public Meeting list of
codes can be found on the CMS website
at https://www.cms.gov/Medicare/
Medicare-Fee-for-Service-Payment/
ClinicalLabFeeSched/
index.html?redirect=/
ClinicalLabFeeSched/. Section
1833(h)(8)(B)(iii) of the Act requires that
we convene the public meeting not less
than 30 days after publication of the
notice in the Federal Register. The
CLFS requirements regarding public
consultation are codified at 42 CFR
414.506.
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 85, Number 86 (Monday, May 4, 2020)]
[Notices]
[Pages 26474-26475]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09400]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2020-0050]
Advisory Board on Radiation and Worker Health
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting of the Advisory Board on Radiation and
Worker Health (ABRWH). This meeting is open to the public, but without
an oral public comment period. The public is welcome to listen to the
meeting by joining the audio conference (information below). The audio
conference line has 150 ports for callers.
DATES: The meeting will be held on June 24, 2020, 11 a.m. to 1 p.m.,
EDT.
Written comments must be received on or before June 18, 2020.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0050 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Rashaun Roberts, Ph.D., Centers for Disease Control
and Prevention, 1600 Clifton Road NE, MS C-24, Atlanta, GA 30329-4027,
Attn: ABRWH Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Meeting information: The USA toll-free dial-in number is 1-866-659-
0537; the pass code is 9933701.
FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090 Tusculum Avenue, Mailstop C-24,
Cincinnati, Ohio 45226, Telephone (513) 533-6800, Toll Free 1(800)CDC-
INFO, Email [email protected].
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule, advice on methods of dose reconstruction which have
also been promulgated by HHS as a final rule, advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program, and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC). In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, and rechartered under Executive Order
13889 on March 22, 2020, and will terminate on March 22, 2022.
Purpose: This Advisory Board is charged with (a) providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advising the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Public Participation
Written Public Comment: The public is welcome to submit written
comments in advance of the meeting. Comments should be submitted on or
before June 18, 2020. All requests must contain the name, address, and
organizational affiliation of the individual, as well as the topic
being addressed. Written comments should not exceed one single-spaced
typed page in length. Written comments received in advance of the
meeting will be included in the official record of the meeting.
Comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted to the docket.
Matters to be Considered: The agenda will include discussions on:
Work Group and Subcommittee Reports; Update on the Status of SEC
Petitions; Plans for the August 2020 Advisory Board Meeting; and
Advisory Board Correspondence. Agenda items are subject to change as
priorities dictate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
[[Page 26475]]
Dated: April 28, 2020.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-09400 Filed 5-1-20; 8:45 am]
BILLING CODE 4163-18-P
